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Abstract
Introduction: Identification of patients who are in early stages of lupus is currently done through clinical
evaluation and is not greatly facilitated by available diagnostic tests. Profiling for patient characteristics and
antibody specificities that predict disease would enhance the ability of physicians to identify and treat early cases
prior to onset of organ damaging illness.
Methods: A group of 22 patients with 4 or fewer diagnostic criteria for lupus were studied for changes in clinical
and autoantibody profiles after a mean follow up period of 2.4 years. An array with more than 80 autoantigens
was used to profile immunoglobulin G (IgG) and immunoglobulin M (IgM) autoantibodies. Correlations with clinical
disease progression were examined.
Results: 3 of the 22 patients (14%) added sufficient criteria during follow up to satisfy a diagnosis of systemic
lupus erythematosus (SLE) or to acquire a diagnosis of SLE renal disease. Patients who progressed were all females
and were younger than those who did not progress (P=0.00054). IgG but not IgM autoreactivity showed greater
increases in the progressor group than in the non-progressor group (P=0.047). IgG specificities that were higher at
baseline in progressors included proliferating cell nuclear antigen (PCNA), beta 2 microglobulin, C1q and
hemocyanin (P<0.019). Progressors had significant increases in La/SSB and liver cytosol type 1 (LC1) IgG
autoantibodies over the period of evaluation (P≤0.0072). A quantitative risk profile generated from baseline
demographic and autoantibody variables yielded highly different scores for the progressor and non-progressor
groups (P=1.38 × 10-7)
Conclusions: In addition to demographic features, autoantibody profiles using an expanded array of specificities
were correlated with the risk of progressive disease in patients with lupus. These findings suggest the feasibility of
developing a simple diagnostic that could be applied by nonspecialists to screen for lupus and permit effective
triage for specialty care.
Introduction
The onset of systemic lupus erythematosus (SLE) may
be an insidious process that can go unrecognized by the
patient or by the primary care provider in the early
phases. This is in part because the symptoms of SLE are
heterogeneous and involve disparate organ systems and
also due to the fact that early manifestations such as
sun sensitivity, skin rash, chest discomfort and joint
pains are relatively common complaints that are usually
associated with non-SLE causes [1,2]. Conversely, the
most serious organ involvement, acute kidney injury,
may go completely unrecognized in the early stages.
Another impediment to early detection is that patients
with SLE usually have onset at relatively young ages
when chronic organ-damaging illness is unexpected.
When SLE is suspected, testing for antinuclear antibo-
dies (ANA) is usually carried out. While ANA positivity
is associated with SLE in almost all cases, the high pre-
valence of ANA positivity in the general population,
which approaches 25%, means that most individuals
with ANAs do not in fact have SLE or a related autoim-
mune disease. So the interpretation of ANA positivity in
the setting of vague symptoms is not straightforward,
and the many positive results obtained in practice dis-
tract focus away from the few individuals who are in
fact at high risk [3].
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Improving the accuracy of early SLE diagnosis would be
greatly aided by the availability of blood markers that have
greater disease specificity in the early stages. One approach
to accomplishing this objective is to expand profiling for
autoantibody expression with the goal of identifying speci-
ficities that signal a high risk of future disease [4]. Since
SLE is associated with more than 100 different autoantibo-
dies [5] and many are present years prior to SLE diagnosis
[6], it is reasonable to postulate that some of these might
appear early and herald future disease.
A useful group of patients for study of early SLE are
those individuals who have some features of SLE but who
do not have a full complement of the defined criteria
needed to establish the diagnosis with certainty. These
individuals have been designated as having incomplete
lupus, or ILE, and it is likely that a subset of these patients
is in the early stages of SLE [7,8].
The present study was designed to determine whether
clinical evolution of lupus-related autoimmunity can be
correlated with expressed autoantibodies. An objective is
to identify specificities that may be useful for distinguish-
ing those individuals who are at high risk of disease
progression. These studies made use of a slide-based
autoantigen array for 80 specificities that has been
described previously [9]. The findings suggest that devel-
opment of a risk scale for lupus progression can be devel-
oped using demographic and autoantibody profile data.
Materials and methods
Study subjects
Serum samples were from the Dallas Regional Autoim-
mune Disease Registry (DRADR), which has been
described previously [9,10]. Patients were recruited from
at the University of Texas Southwestern Medical Center
clinics at Parkland Hospital and the Aston Ambulatory
Care Center. Additional patients were from a local com-
munity-based practice. Classification of clinical syndrome
or disease was made at the time of registry enrollment.
Patient examination, interview and medical record review
were used to determine the presence of SLE criteria. Indi-
viduals with fewer than four criteria were designated as
incomplete lupus (ILE). All individuals provided written
informed consent for enrollment in the registry and the
research carried out has been approved by the UT South-
western Institutional Review Board.
Samples from 22 individuals in DRADR with four or
fewer SLE criteria, and who had at least two samples
drawn in the past 5 years, were utilized for this analysis
(Table 1). The mean (standard error of the mean, SEM)
age at the time of the baseline enrollment visit was 48.5
(2.4) years, with a range of 27 to 72 years, and the major-
ity of samples (86%) were from females. The mean num-
ber of lupus criteria present at baseline was 2.1 (SEM,
0.2). One individual who was enrolled as ILE was found
later to have four criteria, and thus had 4 criteria at the
time of enrollment. No patients were on high-dose corti-
costeroids or cyclophosphamide during the period of
study. There were no clinical criteria utilized to identify
which individuals to resample; the second visit was deter-
mined only by availability. Patients had repeat samples
drawn when they were encountered in our clinics or they
were contacted to come to the research clinic for a repeat
visit. The mean (SEM) time between blood draws was 2.4
(0.4) years and ranged from 0.5 to 6.5 years. Serum sam-
ples were processed and stored at -80°C in multiple
aliquots.
Each patient in DRADR has had measurement of ANA
using an ELISA (Inova, San Diego CA), as described pre-
viously [11]. The positive ANA range in this assay is
defined by the manufacturer as greater than 20 ELISA
units (EU). The correlation between ELISA ANA mea-
surement and the standard immunofluorescence assay
(IFA) on Hep-2 cells has been examined previously in
15 DRADR patients with SLE. Scores for IFA positivity
described as negative, positive and strongly positive had
corresponding mean EU of 9.02 ± 2.9 (mean ± SEM),
31.0 ± 11.8 and 100 ± 22.4 and the correlation between
the two measurements was statistically significant (P =
0.039). The average ANA was 117.8 (SEM, 19.0) EU, and
four of the twenty-two individuals (18%) had ANA values
less than 20 EU at the initial visit (Table 1). ANA mea-
surements were repeated in 18 of the 22 subjects at least
once and changes were not significant (P = 0.166). Nota-
bly, no individual developed or lost ANA positivity on
repeat testing.
Autoantigen array assays
All of the samples, including the first and second visits
for each patient, were analyzed in one batch. Each serum
sample was diluted as described previously and then
applied to arrays in duplicate [9,11]. Autoantibodies were
detected with Cy3-labeled anti-human IgG and Cy-5
labeled anti-human IgM on parallel arrays. Imaging and
calculation of mean fluorescence intensity corresponding
Table 1 Characteristics of the study group
Characteristic Value
Number of patients 22
Age (years) 48.5 ± 2.4*
Female gender (%) 86
African-American (%) 18
Hispanic/Latino (%) 18
ANA positive by ELISA (%) 82
ANA value (Elisa units)** 117.8 ± 19.0*
SLE criteria at Visit 1 2.1 ± 0.2*
*Values represent mean and standard error of the mean. **Positive values
defined as > 20 Elisa units. ANA: antinuclear antibodies; SLE: systemic lupus
erythematosus.
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to the specificity of each autoantibody were carried out as
described previously [11]. Values were expressed as nor-
malized mean fluorescent intensities (MFI) using stan-
dard control antigens on each slide. Heat maps were
generated using open source Cluster and Treeview pro-
grams (Eisen Software, Berkeley, CA, USA) [12]. The
coefficient of variation for the slide-based array, based on
repeat testing of patient and healthy control samples and
considering all 80 specificities, is approximately 40%.
Statistical analysis
Descriptive statistics were used to define variables, and
data are shown as mean and SEM. Patient subgroups
were compared by unpaired Student’s t-test using Graph
Pad Prism 5.0 (La Jolla, CA, USA). P-values < 0.05 were
considered significant, except where otherwise indicated.
Correlations for multiple comparisons were not carried




Review of medical records and information collected at
the return visit were utilized to determine whether the
patients had accumulated additional criteria after the
initial blood sampling [13,14]. Three of the twenty-two
patients (14%) acquired additional lupus criteria over an
average follow-up period of 3.8 ± 0.6 years (Table 2). Two
of these were designated as ILE to SLE progressors and
the third, who was enrolled as ILE but later recognized to
have four criteria, acquired a new diagnosis of renal lupus.
All three of these patients were designated as progressors
(Prog). This rate of progression is similar to what has been
reported by others [15]. The three progressors were
female, with an age range of 27 to 33 years at the baseline
visit, and their average age (30 years) was significantly
lower than in the remaining nonprogressors (NProg), who
had an average age of 51 years (range 35 to 72 years, P =
0.00054). Baseline ANA measured by ELISA tended to be
higher in the Prog group (154 EU) than in the NProg
group (112 EU), but this difference was not statistically
significant (P = 0.46).
IgG autoantibodies
The baseline IgG autoantigen array data for all indivi-
duals were examined using a supervised clustering algo-
rithm (Figure 1). The Prog patients had downregulated
levels of IgG antibodies to a group of structural proteins
including entaktin, fibrinogens, heparin sulfate proteo-
glycan (HSPG) and laminin while other specificities
related to nuclear components (chromatin, Ku), RNA
(U1-snRNPs, Ro/SSA, La/SSB) and thyroid autoantigens
(thyroid peroxidase, TPO, and thyroglobulin) were
upregulated.
Changes in IgG autoreactivity over time between the
two visits were then calculated in two steps. First, differ-
ences in MFI value for each autoantibody were calculated
as visit 2 minus visit 1 values. Then, the mean values for
all IgG’s on the array were computed for each individual
subject. An increased value would reflect a higher burden
of IgG class autoreactivity at the second visit. IgG auto-
reactivity was increased in all three of the ILE Prog indi-
viduals, while more than half of the NProg individuals
with ILE had negative values, consistent with a decreased
burden of IgG autoantibodies on follow-up (Figure 2).
The difference between the two groups in change in
overall IgG autoreactivity between visits was statistically
significant (P = 0.047). This finding suggests that clinical
progression is more likely to occur in patients who are
accumulating additional IgG autoantibodies.
Individual baseline IgG autoantibodies were then
examined to identify those that were potentially useful
in distinguishing subsequent ILE progression subgroups.
Fifteen IgGs were significantly different (P < 0.05) in the
Prog vs. NProg patient groups. Of these, seven had
Table 2 Lupus features in study subjects at baseline and
follow-up visits
Subject Baseline SLE criteria* Follow-up SLE criteria
1 ANA, heme, APL (RF)
2 ANA, arthritis
3 ANA (SSA)
4 ANA, arthritis, Sm
5 ANA
6 ANA (SSA, SSB)
7 ANA, photo, mucosal
8 ANA, photo
9 ANA, arthritis, dsDNA







17 ANA, photo, serositis
18 ANA, discoid, heme
19 ANA, photo (Scl70)
20 ANA, photo, heme,
dsDNA**
LN† class V, mucosal, arthritis,
serositis
21 ANA discoid, photo, APL, heme
22 ANA malar, discoid, photo,
mucosal, arthritis, dsDNA
*Criteria are malar: malar rash; mucosal: mucosal ulcers; serositis: pleurisy,
pericarditis; renal: renal disorder; heme: hematologic disorder; photo:
photosensitivity. Immunologic disorder elements are listed separately (APL:
antiphospholipid antibodies, dsDNA antibodies). Autoimmune features that
are not part of systemic lupus erythematosus (SLE) criteria are listed in
parentheses. **Patient was enrolled as ILE and subsequently found to have
four SLE criteria. † LN: lupus nephritis.
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mean expression levels > 4.0 MFI units: hemocyanin,
formiminotransferase cyclodeaminase or liver cytosol
type 1 (LC1), thyroglobulin, C1q, proliferating cell
nuclear antigen (PCNA), b2 microglobulin and TPO
(Figure 3). Although each of these showed some overlap
between Prog and NProg groups, it is apparent that
patients with low expression levels for these IgGs uni-
formly did not progress to SLE or SLE/renal.
Examination of individual IgG autoantibodies in the
two patient subsets revealed significant differences in
values between the two visits at a level of P < 0.01 for
six specificities: dsRNA, hemocyanin, La/SS-B, LC-1,
PL-7 and TPO. Two of the three progressors showed
increases in SS-A-related antigens, either Ro/SS-A 60kD
or SS-A/SS-B and all three showed increases in La/SS-B.
Notably, while some of the non-progressors showed
decreases in these autoantibodies, none showed an
increase in La/SS-B or LC-1 (Figure 4).
IgM autoantibodies
Absolute expression levels of IgM autoantibodies were
generally lower than for IgG. The supervised clustering
of the baseline IgM array showed generally lower levels
of antibodies to RNA and nuclear antigens for the Prog
patients while reactivity with some thyroid and struc-
tural proteins was increased (Figure 1, right panel). The
highest absolute IgM values were observed for antibo-
dies to the SSA/SSB autoantigen and a trend towards
higher levels of IgM anti-SSA/SSB in Prog than in
NProg patients was observed (P = 0.08) (Figure 5).
IgG 
IgM 
Figure 1 Supervised clustering using Cluster/Treeview software was carried out with normalized signal intensities for baseline IgG
(left) and IgM (right) autoantibodies in ILE patients. Red represents values greater than the row mean and green represents values below
that mean; gray corresponds to missing data. All Prog patients (progressors) are grouped together on the right side of each array and are
indicated by rectangles.
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Quantitative risk assessment
Several scoring systems for lupus risk were devised
based on the data generated in this study. The first used
demographic features alone as a linear three-point scale,
assigning one point each for the presence of the follow-
ing features: female gender, baseline ANA > 200 units,
baseline age < 40 years. The Prog group of three
patients had a mean score of 2.67 on this scale, which
was significantly higher than the score of 1.15 in the
NProg group (P = 6.3 × 10-4). Deriving a four-point
scale by adding to this score one point for an increase
in overall IgG autoreactivity on the array and adding
zero points for decreased IgG autoreactivity, yielded
scores of 3.67 and 1.47 in the two groups (P = 3.4 × 10-
4). A five-point scale was then constructed incorporating
values for the seven IgG autoantibodies that were signif-
icantly different at baseline in the Prog and NProg
groups (Figure 2). To turn the specific IgG values into a
single score, a value of 1 was assigned for expression
levels above the overall mean for each autoantibody, and
a value of 0 was assigned for levels below the mean,
similar to the approach we have used previously in gene
expression studies [16]. The values for all seven antibo-
dies were totaled so that each patient had an autoanti-
body score in the range of 0 to 7. Adding this variable
to create a five-point score yielded values of 10.00 in the
Prog and 2.89 in the NProg groups (P = 1.38 × 10-7).
Discussion
The search for readily-accessible blood biomarkers of
disease risk is a major focus of biomedical research in
many areas. The development over 50 years ago of a
simple slide-based assay for serum ANAs is in fact an
example of a paradigm-shifting biomarker. This single
test was the key to the finding that patients with a wide
array of clinical pathology in multiple organ systems, in
fact shared a common autoimmune etiology [3]. With-
out the ANA blood test it would have taken far longer
to define SLE and develop effective treatments. The cur-
rent challenge is to find more specific indicators of high
risk disease in early or even pre-clinical stages of SLE
when interventions have significant disease-modifying
potential [17,18]. We have used the designation of
incomplete lupus (ILE) to identify individuals with less
than 4 criteria, as a group that is at risk for progression
of disease. One of the patients in the current study sub-
sequently was recognized as having four criteria,
although clinically, this individual was treated as ILE
with hydroxychloroquine and subsequently progressed
to develop renal involvement. This illustrates that
although the ILE definition is somewhat arbitrary, it
does have value in defining a population at risk for pro-
gressive illness.
A major tool employed in the current studies is the
slide-based autoantigen array, which is in effect a scale-
up of the classic slide-based ANA using a broad spec-
trum of autoantigens. Since many investigations have
clearly documented that autoantibodies appear in the
circulation prior to onset of clinically apparent SLE, it is
reasonable to postulate that a subset of the autoantibo-
dies on the array may be biomarkers predictive of risk
[11]. The results presented here suggest that longitudi-
nal evaluation of patients can provide useful insights
into features that predict higher risk of progressive auto-
immunity and support the hypothesis that the ILE
patient category includes some individuals who are in
evolving stages of disease [15]. The risk features include
the relatively straightforward ones of female gender and
age less than 40 years, which are also risk factors for
development of ANA positivity itself [11]. Furthermore,
having a high baseline ANA and an increase in IgG
autoreactivity added to the risk score. The autoantigen
arrays also point to a set of baseline IgG autoantibodies
that further elevate the risk of progression to SLE. Vali-
dation of these observations and the proposed or alter-
native risk scores in a larger, prospectively collected
sample will be required to determine whether these
autoantibodies are in fact prognostic biomarkers.
Autoimmune responses modulate over time, and show
patterns consistent with epitope spreading [19]. Antibo-
dies to Ro/SSA are among the earliest to appear prior to
SLE diagnosis, and responses to these epitopes show evi-
dence of spread [20]. The present study showed that IgM
and IgG antibodies Ro/SSA and La/SSB autoantigens
may be related to disease progression. None of the
Figure 2 Calculated change in total IgG autoreactivity between
visit 1 and visit 2 in Prog (progressor) and NProg
(nonprogressor ) subgroups. Change was calculated for each
autoantibody on the IgG array as visit 2 minus visit 1 values, and
then these individual autoantibody change values were averaged
for the whole array, yielding one overall result for each patient.
Values > 0 correspond to increased IgG autoreactivity at visit 2. The
two groups were compared using an unpaired Student’s t-test.
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patients with progression had decreases in IgG antibodies
to La/SSB over the period of follow-up and conversely
none of the nonprogressors showed increased levels of
these autoantibodies. The La/SSB changes are of interest
in view of animal model data demonstrating that the
RNA recognition motif of La/SSB mediates epitope
spreading by triggering B cells to diversify the expressed
repertoire through a molecular mimicry mechanism [21].
Whether the early upregulation of La/SSB autoantibodies
in humans has specificity for later development of SLE or
other autoimmune disorders remains undetermined [22].
Since Ro/SSA and La/SSB autoantibodies are readily
measured in the clinical laboratory, these could be clini-
cally useful predictive tests as others have suggested [23].
On the other hand, the overall prevalence of Ro/SSA and
La/SSB in SLE is not high enough to deliver sufficient
sensitivity to be a useful screening tool. Furthermore, the
thyroid autoantibodies might actually indicate that the
Figure 3 Baseline levels of IgG autoantibodies in Prog (progressor) and NProg (nonprogressor) patient subsets. Values represent mean
fluorescence intensities (MFI). The two patient groups were compared using an unpaired Student’s t-test. The seven autoantibodies shown
represent those with significant differences (P < 0.05) between Prog and NProg subsets, which also had absolute expression values of at least
4 MFI.
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autoimmune problem is primarily in that gland. Overall,
the use of a multiplex set of antibodies to develop a risk
score is likely to be a more robust approach.
A screening test for risk based on clinical, demo-
graphic and laboratory features would be potentially
useful in the primary care setting to help with appropri-
ate triage for specialty care. The high volume of ANA
positive referrals to rheumatology clinics might be more
efficiently managed if a risk assessment tool were avail-
able. A scale that could reliably identify patients at high
risk for progression also would be potentially useful to
identify candidates for preclinical treatment protocols
designed to delay, ameliorate or prevent progression to
SLE. Hydroxychloroquine is one candidate medication
that might be used for this purpose, since other data
suggest that use of this drug in early disease may delay
the onset of SLE [24]. Other treatments such as Vitamin
D, statins and peptide vaccination have been also dis-






















































































Figure 4 Changes in mean fluorescence intensity (MFI) values between the two visits for four autoantibodies in the Prog (progressor)
and NProg (nonprogressor) patient groups. Two of these autoantibodies, La/SSB and LC-1, showed changes that were significantly related to
progression status. The SSA/Ro 60 kD and SSA/SSB specificities showed marked changes in two of the three Prog patients. None of these four
autoantibodies showed decreases in any of the Prog patients over the followup interval.
Figure 5 Baseline mean fluorescence intensity (MFI) values for
IgM autoantibodies directed against the SSA/SSB antigen. No
patients with initial IgM-SSA/SSB values less than 20 MFI showed
progression of disease features during the follow-up period.
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There are several significant limitations to the present
study. These include the small sample size and retro-
spective design, which potentially introduces bias in
patient selection. Furthermore, the relatively short per-
iod of evaluation may not have permitted capture of
additional changes that might become manifest only
with longer follow-up. Other findings indicate that at
least some ILE or ANA-positive patients experience
years of latency and accumulating autoimmunity prior
to disease onset [25].
Conclusions
Patients with autoimmune markers of lupus include a
subset with evolving disease in whom SLE may become
manifest. Female gender, age less than 40 years and high
ANA levels are significant risk factors for progression of
disease. Autoantibodies to Ro/SSA and La/SSB may be
of additional use in detecting individuals at risk for SLE
progression, and other autoantibodies, especially in the
IgG class, also may have significant predictive value.
Further longitudinal studies to determine the validity of
the proposed risk profile will be of interest. Ultimately,
application of these tools to the design of preclinical
treatment strategies designed to ameliorate or prevent
manifestations of SLE should be considered.
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